Accelerating Early Phase Clinical Development in the UK:

Posted:
24
October 2011

The Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI) welcomes you to attend its annual meeting being held on Friday 18th November at the Wellcome Collection Conference Centre, London from 13h30 to 17h30.The Association has been in existence for over nearly 2 decades and has forged links with both other scientific societies with similar interests and with professional bodies such as the ABPI and ICR. The AHPPI's mission is to offer a framework for discussion and to exchange on current topics in applied Human Pharmacology and early phase drug development. Its aim is also to provide training, education and guidance and provide a forum for innovation and the development of new methods and efficiencies.The topic of this meeting will focus on "Accelerating Early Phase Clinical Development in the UK", and as always we expect to have a panel of excellent speakers from such organisations as ABPI, MHRA, NHS, pharmaceutical and CRO industries. For further details for what's in store for the day, please click here to view the full meeting agenda or here to register.Furthermore there will be the opportunity to attend the guided tours of the Wellcome collections and exhibitions. If you are interested in attending a tour on the day of the AHPPI meeting, please contact us for more details.This meeting has been awarded four Continuing Professional Development points by the Faculty of Pharmaceutical Medicine and is open to AHPPI members and non-members. On behalf of the AHPPI we cordially invite you to attend and look forward to seeing you next month!

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more